

Gastroenterology

Volume 157 / Number 5

November 2019

www.gastrojournal.org

TABLE OF
CONTENTS

Contents

ON THE COVER

See article by Fan et al on page 1352 for additional information.



IN MEMORIAM

1173 Kurt J. Isselbacher, MD (1925–2019)

L. S. Friedman and D. K. Podolsky

COVERING THE COVER

1175 *A. T. Chan and C. S. Williams*

COMMENTARY

1177 **Lessons Learned From and Future Opportunities for Global Health Endeavors by 2 Academic Gastroenterology Units**

T. A. Carr, S. Okello, F. F. Some, and K. E. Corey

MEETING SUMMARY

1180 **Targeting Gut Microbiome Interactions in Service-Related Gastrointestinal and Liver Diseases of Veterans**

J. S. Bajaj, A. Sharma, and P. K. Dudeja

MENTORING, EDUCATION, AND TRAINING CORNER

1184 **How to Perform a High-Quality PerOral Endoscopic Myotomy?**

M. A. Khashab, A. Sethi, T. Rosch, and A. Repici

EDITORIALS

1190 **Prophylactic Clip Closure Clarified: The Question Is Not Whether to Clip, But When**

D. K. Rex

See Pohl H et al on page 977; and Albeniz E et al on page 1213.

Video Related article in CGH Hot Papers From New Investigators

CME quiz Editorial accompanies this article Additional online content available Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi monthly in January and May) in two indexed volumes by Elsevier Inc, 230 Park Avenue, New York, NY 10169-0901, USA. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to Elsevier, Journal Returns, 1799 Highway 50 East, Linn, MO 65051, USA. 2019 US subscription rates: individual, \$739.00; student and resident, \$282.00. Outside of the U.S. and possessions: individual, \$968.00; student and resident, \$562.00; surface delivery, no additional charge; air mail delivery, add \$78.00. Prices subject to change without notice.

1192 Can Colonoscopy Sow the Seeds of Colorectal Cancer?*J. E. East*

See Backes Y et al on page 1222.

GASTROENTEROLOGY IN MOTION**1196 Strain-Photoacoustic Imaging as a Potential Tool for Characterizing Intestinal Fibrosis**CME V *Y. Zhu, L. A. Johnson, J. M. Rubin, H. Appelman, L. Ni, J. Yuan, X. Wang, P. D. R. Higgins, and G. Xu***CLINICAL CHALLENGES AND IMAGES IN GI****1199 An Unusual Cause of Ileus in a Cardiovascular Surgery Patient***C. Meade and M. Halland***1201 A Unique Cause of Gastric Polyposis***A. Anderson, R. Plummer, and J. M. Abraham***1203 Currant Jelly-Like Clot-Induced Acute Pancreatitis***M. Horumbă, A. Larghi, and M. Rimbaş***1205 Sigmoid-Derived Neovaginal Hemorrhage in a Transgender Patient***P. J. Riddle Jr., F. Rashti, and D. Ahuja***ELECTRONIC CLINICAL CHALLENGES AND IMAGES IN GI**For a full list, please see the table of contents online at www.gastrojournal.org.**PRACTICAL TEACHING CASES****1207 Bloody Diarrhea and Weight Loss in a Patient in Remission From Ulcerative Colitis**CME *L. Tsang, N. Banerjee, and J. H. Tabibian***1210 An Enigmatic Mass in the Ascending Colon**CME *A. Gavrić, R. Dežman, and B. Štabuc***ORIGINAL RESEARCH****Full Reports****Clinical—Alimentary Tract****1213 Clip Closure After Resection of Large Colorectal Lesions With Substantial Risk of Bleeding**E CME WWW *E. Albéniz, M. A. Álvarez, J. C. Espinós, O. Nogales, C. Guarner, P. Alonso, M. Rodríguez-Téllez, A. Herreros de Tejada, J. Santiago, M. Bustamante-Balén, J. Rodríguez Sánchez, F. Ramos-Zabala, E. Valdivielso, F. Martínez-Alcalá, M. Fraile, A. Elosua, M. F. Guerra Veloz, B. Ibáñez Beroiz, F. Capdevila, and M. Enguita-Germán*

See editorial on page 1190

During undergoing endoscopic mucosal resection, successful clip closure of mucosal defects in patients with large nonpedunculated colorectal lesions can reduce their risk of later bleeding.

1222 Tumor Seeding During Colonoscopy as a Possible Cause for Metachronous Colorectal CancerV E WWW *Y. Backes, T. C. J. Seerden, R. S. F. E. van Gestel, O. Kranenburg, I. Ubink, R. M. Schiffelers, D. van Straten, M. S. van der Capellen, S. van de Weerd, W. W. J. de Leng, P. D. Siersema, G. Johan A. Offerhaus, F. H. Morsink, W. Ramphal, J. Terhaar Sive Droste, A. U. G. van Lent, J. M. J. Geesing, F. P. Vleggaar, S. G. Elias, M. M. Lacle, and L. M. G. Moons*

See editorial on page 1192

When endoscopists collected biopsies from a colorectal tumor and then examine a different section of the intestine with the same endoscope, tumor cells might be transferred to a new location, resulting in secondary or metachronous colorectal tumors.

1233 Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's Disease

www

P. Hindryckx, V. Jairath, G. Zou, B. G. Feagan, W. J. Sandborn, J. Stoker, R. Khanna, L. Stitt, T. van Viegen, L. M. Shackelton, S. A. Taylor, C. Santillan, B. Mearadji, G. D'Haens, M.-P. Richard, J. Panes, and J. Rimola

The authors developed a new system to determine the severity of perianal fistulas in patients with Crohn's disease based on 6 factors collected during magnetic resonance imaging.

Clinical—Liver**1245 Development and Validation of a Model Consisting of Comorbidity Burden to Calculate Risk of Death Within 6 Months for Patients With Suspected Drug-Induced Liver Injury**

www

M. Ghabril, J. Gu, L. Yoder, L. Corbitto, A. Ringel, C. D. Beyer, R. Vuppalachchi, H. Barnhart, P. H. Hayashi, and N. Chalasani

The authors developed a system to determine risk of death in patients suspected of having drug-induced liver injury.

1253 Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma

www

A. G. Singal, N. E. Rich, N. Mehta, A. D. Branch, A. Pillai, M. Hoteit, M. Volk, M. Odewole, S. Scaglione, J. Guy, A. Said, J. J. Feld, B. V. John, C. Frenette, P. Mantry, A. S. Rangnekar, O. Oloruntoba, M. Leise, J. H. Jou, K. R. Bhamidimarri, L. Kulik, G. N. Ioannou, A. Huang, T. Tran, H. Samant, R. Dhanasekaran, A. Duarte-Rojo, R. Salgia, S. Eswaran, P. Jalal, A. Flores, S. K. Satapathy, S. Kagan, P. Gopal, R. Wong, N. D. Parikh, and C. C. Murphy

Treatment of hepatitis C virus with direct-acting antiviral agents in patients who have been successfully treated for liver cancer increases overall survival.

1264 Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores

www

G. N. Ioannou, L. A. Beste, P. K. Green, A. G. Singal, E. B. Tapper, A. K. Waljee, R. K. Sterling, J. J. Feld, D. E. Kaplan, T. H. Taddei, and K. Berry

Patients with cirrhosis or severe fibrosis before treatment for hepatitis C virus (HCV) infection should be monitored for hepatocellular carcinoma, even if their HCV infection is cured.

Basic and Translational—Alimentary Tract**1279 Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases**

www

K. Aden, A. Rehman, S. Waschina, W.-H. Pan, A. Walker, M. Lucio, A. M. Nunez, R. Bharti, J. Zimmerman, J. Bethge, B. Schulte, D. Schulte, A. Franke, S. Nikolaus, J. O. Schroeder, D. Vandeputte, J. Raes, S. Szymczak, G. H. Waetzig, R. Zeuner, P. Schmitt-Kopplin, C. Kaleta, S. Schreiber, and P. Rosenstiel

The authors identify baseline gut microbial metabolic functions that affect therapeutic efficacy of anti-TNF therapy in IBD in a mechanism involving synthesis of short-chain fatty acids.

1293 Inhibiting PGGT1B Disrupts Function of RHOA, Resulting in T-Cell Expression of Integrin $\alpha 4\beta 7$ and Development of Colitis in Mice

www

R. López-Posadas, P. Fastancz, L. d. C. Martínez-Sánchez, J. Panteleev-Ivlev, V. Thonn, T. Kisseleva, L. S. Becker, A. Schulz-Kuhnt, S. Zundler, S. Wirtz, R. Atreya, B. Carlé, O. Friedrich, S. Schürmann, M. J. Waldner, C. Neufert, C. H. Brakebusch, M. O. Bergö, M. F. Neurath, and I. Atreya

PGGT1B regulates activation of RhoA. Patients with inflammatory bowel diseases have reduced levels of PGGT1B, which might contribute to their chronic intestinal inflammation.

1310 Interferon Lambda Promotes Paneth Cell Death Via STAT1 Signaling in Mice and Is Increased in Inflamed Ileal Tissues of Patients With Crohn's Disease

C. Günther, B. Ruder, I. Stolzer, H. Dorner, G.-W. He, M. T. Chiriack, K. Aden, A. Strigli, M. Bittel, S. Zeissig, P. Rosenstiel, R. Atreya, M. F. Neurath, S. Wirtz, and C. Becker

Strategies to reduce IFNL signaling might be developed for treatment of patients with Crohn's disease that affects the terminal ileum.

1323 Inflammation-induced Occludin Downregulation Limits Epithelial Apoptosis by Suppressing Caspase-3 Expression

W.-T. Kuo, L. Shen, L. Zuo, N. Shashikanth, M. L. D. M. Ong, L. Wu, J. Zha, K. L. Edelblum, Y. Wang, Y. Wang, S. P. Nilsen, and J. R. Turner

Intestinal tissues from inflammatory bowel disease patients have reduced expression of the barrier protein occludin. Inflammation-induced downregulation of occludin might prevent damage in intestinal tissues.

1338 Infliximab-Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies

H. Bar-Yoseph, S. Pressman, A. Blatt, S. Gerassy Vainberg, N. Maimon, E. Starosvetsky, B. Ungar, S. Ben-Horin, S. S. Shen-Orr, and Y. Chowers, on behalf of the Israeli IBD Research Nucleus

The authors identified mechanisms of immune response against Infliximab and suggest that patients be given exact doses that can treat the disease but not activate an immune response against the drug.

Basic and Translational—Liver**1352 ECM1 Prevents Activation of Transforming Growth Factor β , Hepatic Stellate Cells, and Fibrogenesis in Mice**

W. Fan, T. Liu, W. Chen, S. Hammad, T. Longerich, I. Hausser, Y. Fu, N. Li, Y. He, C. Liu, Y. Zhang, Q. Lian, X. Zhao, C. Yan, L. Li, C. Yi, Z. Ling, L. Ma, X. Zhao, H. Xu, P. Wang, M. Cong, H. You, Z. Liu, Y. Wang, J. Chen, D. Li, L. Hui, S. Dooley, J. Hou, J. Jia, and B. Sun

The authors identified a protein produced by hepatocytes, called ECM1, that prevents development of fibrosis in livers of mice. Liver tissues from patients with cirrhosis have lower levels of ECM1.

1368 Small-Molecule Inhibitors of Cyclophilins Block Opening of the Mitochondrial Permeability Transition Pore and Protect Mice From Hepatic Ischemia/Reperfusion Injury

M. Panel, I. Ruiz, R. Brillet, F. Lafdil, F. Teixeira-Clerc, C. T. Nguyen, J. Calderaro, M. Gelin, F. Allemand, J.-F. Guichou, B. Ghaleh, A. Ahmed-Belkacem, D. Morin, and J.-M. Pawlotsky

The new family of small-molecule cyclophilin inhibitors offers promising drug candidates in the context of warm ischemia-reperfusion after liver surgery and, possibly, in many other liver and non-hepatic diseases related to mitochondrial dysfunction involving cyclophilin D.

1383 An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents

A. Moeini, S. Torrecilla, V. Tovar, C. Montironi, C. Andreu-Oller, J. Peix, M. Higuera, D. Pfister, P. Ramadori, R. Pinyol, M. Solé, M. Heikenwälder, S. L. Friedman, D. Sia, and J. M. Llovet

The authors identified a gene signature that associated with risk of HCC development in patients with cirrhosis, as well as a drug that prevents these changes and reduces development of liver tumors in mice with liver fibrosis or steatosis.

1398 Fibrogenic Activity of MECP2 Is Regulated by Phosphorylation in Hepatic Stellate Cells

E. Moran-Salvador, M. Garcia-Macia, A. Sivaharan, L. Sabater, M. Y. W. Zaki, F. Oakley, A. Knox, A. Page, S. Luli, J. Mann, and D. A. Mann

Hepatic stellate cells contribute to development of fibrosis in liver. The protein MECP2 regulates this process and strategies to alter its function might be developed for treatment of liver fibrosis.

Basic and Translational—Pancreas

1413 **Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet**

Y. Luo, Y. Yang, M. Liu, D. Wang, F. Wang, Y. Bi, J. Ji, S. Li, Y. Liu, R. Chen, H. Huang, X. Wang, A. K. Swidnicka-Siergiejko, T. Janowitz, S. Beyaz, G. Wang, S. Xu, A. B. Bialkowska, C. K. Luo, C. L. Pin, G. Liang, X. Lu, M. Wu, K. R. Shroyer, R. A. Wolff, W. Plunkett, B. Ji, Z. Li, E. Li, X. Li, V. W. Yang, C. D. Logsdon, J. L. Abbruzzese, and W. Lu

Acinar cells that express oncogenic KRAS reduce expression of fibroblast growth factor 21 (FGF21). FGF21 might be given to patients for the prevention or treatment of pancreatic cancer.

CONTINUING MEDICAL EDUCATION (CME)/MOC ACTIVITIES

- e14 CME Exam 1: Strain-Photoacoustic Imaging as a Potential Tool for Characterizing Intestinal Fibrosis**
- e16 CME Exam 2: Bloody Diarrhea and Weight Loss in a Patient in Remission From Ulcerative Colitis**
- e17 CME Exam 3: An Enigmatic Mass in the Ascending Colon**
- e18 CME Exam 4: Clip Closure After Resection of Large Colorectal Lesions With Substantial Risk of Bleeding**

SELECTED SUMMARIES

- 1429 Crohn's Disease Connectome Conundrums: Relevance to the Prevalence and Management of Mood Disorders**
D. J. Gracie and A. C. Ford
- 1431 Hepatitis D Virus Infection Revisited**
E. R. Verrier, K. Majzoub, and T. F. Baumert
- 1432 Lynch Syndrome: Widening the Net**
X. Llor

CORRESPONDENCE

- 1435 Ustekinumab and Pregnancy: Continue or Cease Before You Conceive?**
T. AlAmeel and E. Al Sulais
- 1435 Reply**
U. Mahadevan, S. Fisher, L. Riley, C. Chambers, R. Jain, and C. Robinson, and the co-authors of the AGA Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway
- 1436 Can Retrospective Studies Confirm Causes of Drug-Induced Liver Injury?**
M. Yang, Z. Li, and D. Dou
- 1437 RE: Incidence and Etiology of Drug-Induced Liver Injury in Mainland China**
H. Devarbhavi and E. S. Bjornsson
- 1438 RE: Incidence and Etiology of Drug-Induced Liver Injury in Mainland China**
W. Cong, Q. Xin, and Y. Gao
- 1439 Reply**
T. Shen, Y. Mao, and C. Chen

- 1440 Neonatal Life Events and the Risk of Inflammatory Bowel Disease**
J. Sabino, J. Torres, J.-F. Colombel, and I. Peter
- 1441 Friend or Foe in Inflammatory Bowel Disease Pathogenesis: Not All Infections Are Equal**
S. C. Shah
- 1442 Events Early in Life, But Not the Neonatal Period, Affect Risk for Later Development of Inflammatory Bowel Disease**
R. L. Mones
- 1443 Reply**
C. N. Bernstein
- e26 Ruxolitinib for the Treatment of Portal Hypertension in a Patient With Primary Myelofibrosis**
H. K. Tan, W. Q. Leow, and P. E. Chang

Access to the full content of Gastroenterology Online is available to all subscribers!

AGA members have seamless access to full *Gastroenterology* content from the AGA Web site. Simply sign in to <http://www.gastro.org>, visit the Publications section of the Web site, and click on *Gastroenterology*. You will be directed to the Journal Web site and will have full access to all content without having to supply a different username and password. Members can also visit <http://www.gastrojournal.org> directly and click on "Activate Online Access." Nonmember subscribers must create an online user account and activate their subscription to access the full text of articles on *Gastroenterology* Online. To activate your individual online subscription, please visit <http://www.gastrojournal.org> and click on "Activate Online Access." To activate your account, you

will need your subscriber account or member number, which you can find on your mailing label, (AGA members must use their 10-digit member number, including leading zeros). If you have any questions regarding your online subscription please call Elsevier Customer Service at (800) 654-2452.

Institutional access to *Gastroenterology* Online will be allowed only by limited site licensing. Further instructions will be available online. Personal subscriptions to *Gastroenterology* Online are for individual use only and may not be transferred. Use of *Gastroenterology* Online is subject to agreement to the terms and conditions of use as indicated online.

AGA Member Number

Your Account Number

**Sample
mailing
label**

GAST0000101864
JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001

1GAST V91-4 1234567-8
JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001